Effie

Amryt is a global biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative treatments for rare and orphan diseases. With a strong and expanding portfolio of commercial and developmental assets, Amryt aims to improve the lives of patients suffering from these debilitating conditions. The company's commercial business includes four orphan disease products: Myalept (metreleptin), Mycapssa (octreotide capsules), Juxtapid (lomitapide), and Oleogel-S10 (Filsuvez). These treatments address various conditions such as leptin deficiency, acromegaly, and Homozygous Familial Hypercholesterolaemia (HoFH). Amryt also has a promising pre-clinical gene therapy candidate, AP103, which offers potential treatment for patients with Dystrophic Epidermolysis Bullosa (EB).Generated from the website

Enlight Bio Inc is a biotechnology company based in Boston, MA, specializing in cutting-edge research and development in the field of genetic engineering and personalized medicine. With a focus on innovative solutions and advancements in healthcare, Enlight Bio Inc is dedicated to pushing the boundaries of scientific discovery and improving patient outcomes through its groundbreaking technologies. Generated from their business information